AxoGen (AXGN) Competitors $15.59 -0.40 (-2.50%) Closing price 04:00 PM EasternExtended Trading$15.70 +0.11 (+0.67%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AXGN vs. SLNO, LIVN, WRBY, EYE, INSP, PRCT, LMAT, AORT, LQDA, and ENOVShould you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Soleno Therapeutics (SLNO), LivaNova (LIVN), Warby Parker (WRBY), National Vision (EYE), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), Artivion (AORT), Liquidia Technologies (LQDA), and Enovis (ENOV). These companies are all part of the "medical equipment" industry. AxoGen vs. Its Competitors Soleno Therapeutics LivaNova Warby Parker National Vision Inspire Medical Systems PROCEPT BioRobotics LeMaitre Vascular Artivion Liquidia Technologies Enovis AxoGen (NASDAQ:AXGN) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations. Which has more volatility and risk, AXGN or SLNO? AxoGen has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.75, meaning that its stock price is 375% less volatile than the S&P 500. Which has better valuation & earnings, AXGN or SLNO? AxoGen has higher revenue and earnings than Soleno Therapeutics. AxoGen is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxoGen$203.27M3.53-$9.96M-$0.10-155.90Soleno Therapeutics$32.66M104.59-$175.85M-$4.14-15.52 Does the media prefer AXGN or SLNO? In the previous week, Soleno Therapeutics had 7 more articles in the media than AxoGen. MarketBeat recorded 22 mentions for Soleno Therapeutics and 15 mentions for AxoGen. Soleno Therapeutics' average media sentiment score of 0.38 beat AxoGen's score of 0.11 indicating that Soleno Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Soleno Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer AXGN or SLNO? AxoGen presently has a consensus target price of $25.75, indicating a potential upside of 65.17%. Soleno Therapeutics has a consensus target price of $115.92, indicating a potential upside of 80.36%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Soleno Therapeutics is more favorable than AxoGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AxoGen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Soleno Therapeutics 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.93 Do insiders and institutionals have more ownership in AXGN or SLNO? 80.3% of AxoGen shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 2.8% of AxoGen shares are owned by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is AXGN or SLNO more profitable? Soleno Therapeutics has a net margin of 0.00% compared to AxoGen's net margin of -2.29%. AxoGen's return on equity of -4.43% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AxoGen-2.29% -4.43% -2.34% Soleno Therapeutics N/A -73.74%-56.67% SummarySoleno Therapeutics beats AxoGen on 11 of the 17 factors compared between the two stocks. Get AxoGen News Delivered to You Automatically Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXGN vs. The Competition Export to ExcelMetricAxoGenMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$717.34M$6.89B$6.04B$10.46BDividend YieldN/A1.17%5.73%4.79%P/E Ratio-155.8826.2185.3127.07Price / Sales3.53191.06586.80189.44Price / CashN/A21.8525.7330.17Price / Book6.615.1712.666.69Net Income-$9.96M$176.38M$3.31B$276.03M7 Day Performance-9.15%-1.46%-0.44%-1.14%1 Month Performance-5.00%6.91%8.70%6.49%1 Year Performance5.98%24.74%76.79%34.44% AxoGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXGNAxoGen2.9509 of 5 stars$15.59-2.5%$25.75+65.2%+8.7%$717.34M$203.27M-155.88450SLNOSoleno Therapeutics4.365 of 5 stars$58.45-1.3%$115.09+96.9%+16.5%$3.15B$32.66M-14.1230LIVNLivaNova2.338 of 5 stars$52.63-1.4%$59.71+13.5%-3.5%$2.91B$1.25B-13.532,900WRBYWarby Parker2.3227 of 5 stars$25.41-3.1%$24.75-2.6%+41.4%$2.76B$771.32M-362.953,780Positive NewsEYENational Vision2.282 of 5 stars$28.15-2.5%$24.73-12.2%+154.6%$2.29B$1.89B-156.3913,411Positive NewsINSPInspire Medical Systems4.846 of 5 stars$76.36-0.3%$154.43+102.2%-64.3%$2.26B$802.80M44.141,246Analyst ForecastPRCTPROCEPT BioRobotics2.973 of 5 stars$35.24-2.0%$70.00+98.6%-54.1%$2.00B$224.50M-22.74430LMATLeMaitre Vascular3.9138 of 5 stars$87.49-0.4%$97.60+11.6%-5.0%$1.99B$219.86M42.47490AORTArtivion3.2425 of 5 stars$40.79-0.6%$43.13+5.7%+55.1%$1.94B$388.54M-97.121,600Analyst ForecastLQDALiquidia Technologies3.3573 of 5 stars$22.86+1.9%$32.38+41.6%+109.5%$1.93B$14M-13.4550ENOVEnovis3.6414 of 5 stars$31.30-2.2%$51.00+62.9%-26.2%$1.83B$2.11B-2.207,367News CoveragePositive News Related Companies and Tools Related Companies SLNO Alternatives LIVN Alternatives WRBY Alternatives EYE Alternatives INSP Alternatives PRCT Alternatives LMAT Alternatives AORT Alternatives LQDA Alternatives ENOV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AXGN) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
